Published in:
01-04-2022 | Cardiac Amyloidosis | ORIGINAL ARTICLE
Quantitation of myocardial 99mTc-HMDP uptake with new SPECT/CT cadmium zinc telluride (CZT) camera in patients with transthyretin-related cardiac amyloidosis: Ready for clinical use?
Authors:
Dimitri Bellevre, MD, Alban Bailliez, MD, PhD, François Delelis, MD, Tanguy Blaire, MD, PhD, Denis Agostini, MD, PhD, Frédéric Mouquet, MD, PhD, Sylvestre Maréchaux, MD, PhD, Alain Manrique, MD, PhD
Published in:
Journal of Nuclear Cardiology
|
Issue 2/2022
Login to get access
Abstract
Background
The aim of this study was to investigate the feasibility of assessing absolute myocardial 99mTc-HMDP uptake in patients with suspected cardiac ATTR using SUV with a whole-body CZT SPECT-CT camera (DNM670CZT).
Methods
Fifteen patients with suspected cardiac ATTR (Perugini ≥ 2) underwent a conventional 99mTc-HMDP planar imaging and a thoracic SPECT/CT using a DNM 670CZT. A control group consisted of 15 patients with negative scintigraphy (Perugini < 2). SUVmax (mg·L−1) and percentage of injected dose (%ID) were calculated in a cardiac volume of interest (VOI) encompassing the left ventricle. VOIs were also placed in the lung, the right pectoris major, and the sternum. A heart-to-lung SUVmax ratio (HLR) was calculated.
Results
All ATTR patients demonstrated an increased cardiac HMDP SUVmax (12.2 ± 3.7 mg·L−1) vs controls (3.5 ± 1.2, P < .0001). Percentage of ID, pectoral uptake and HLR were significantly higher in the ATTR group (1.1 ± 0.3 vs 0.15 ± 0.8, P < .0001; 1.5 ± 0.3 vs 0.9 ± 0.3, P < .0001; 9.7 ± 3 vs 4.3 ± 2.2, P < .0001). Bone uptake was not statistically different between the two groups.
Conclusion
This study demonstrated the feasibility of quantitative 99mTc-HMDP SUVmax measurement using a whole-body SPECT/CT CZT camera in patients with suspected cardiac ATTR.